132 related articles for article (PubMed ID: 8870809)
1. Effects of fructose ingestion on sorbitol and fructose 3-phosphate contents of erythrocytes from healthy men.
Kawaguchi M; Fujii T; Kamiya Y; Ito J; Okada M; Sakuma N; Fujinami T
Acta Diabetol; 1996 Jul; 33(2):100-2. PubMed ID: 8870809
[TBL] [Abstract][Full Text] [Related]
2. Effects of an aldose reductase inhibitor on erythrocyte fructose 3-phosphate and sorbitol 3-phosphate levels in diabetic patients.
Hamada Y; Odagaki Y; Sakakibara F; Naruse K; Koh N; Hotta N
Life Sci; 1995; 57(1):23-9. PubMed ID: 7596218
[TBL] [Abstract][Full Text] [Related]
3. Role of polyol pathway in nonenzymatic glycation.
Hamada Y; Araki N; Horiuchi S; Hotta N
Nephrol Dial Transplant; 1996; 11 Suppl 5():95-8. PubMed ID: 9044317
[TBL] [Abstract][Full Text] [Related]
4. In vitro retinal and erythrocyte polyol pathway regulation by hormones and an aldose reductase inhibitor.
Hotta N; Kakuta H; Koh N; Fukasawa H; Yasuma T; Awaya S; Sakamoto N
Diabetes Res Clin Pract; 1991 Oct; 14(1):29-35. PubMed ID: 1748061
[TBL] [Abstract][Full Text] [Related]
5. Effects of aldose reductase inhibitor (ONO-2235) on human erythrocyte sorbitol concentrations in 75 g oral glucose tolerance tests.
Kamon N; Mabuchi H; Takeda R; Terashima H
Horm Metab Res; 1991 May; 23(5):226-9. PubMed ID: 1908433
[TBL] [Abstract][Full Text] [Related]
6. Effects of high glucose concentrations and epalrestat on sorbitol and myo-inositol metabolism in cultured rabbit aortic smooth muscle cells.
Sakakibara F; Hotta N; Koh N; Sakamoto N
Diabetes; 1993 Nov; 42(11):1594-600. PubMed ID: 8405700
[TBL] [Abstract][Full Text] [Related]
7. Erythrocyte sorbitol level as a predictor of the efficacy of epalrestat treatment for diabetic peripheral polyneuropathy.
Ando H; Takamura T; Nagai Y; Kaneko S;
J Diabetes Complications; 2006; 20(6):367-70. PubMed ID: 17070440
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological properties of fidarestat, a potent aldose reductase inhibitor, clarified by using sorbitol in human and rat erythrocytes.
Sobajima H; Aoki T; Sassa H; Suzuki T; Taniko K; Makino M; Mizuno K; Suzuki T
Pharmacology; 2001 May; 62(4):193-9. PubMed ID: 11359994
[TBL] [Abstract][Full Text] [Related]
9. Epalrestat, an aldose reductase ihibitor, reduces the levels of Nepsilon-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients.
Hamada Y; Nakamura J; Naruse K; Komori T; Kato K; Kasuya Y; Nagai R; Horiuchi S; Hotta N
Diabetes Care; 2000 Oct; 23(10):1539-44. PubMed ID: 11023149
[TBL] [Abstract][Full Text] [Related]
10. Effects of a fructose-rich diet and the aldose reductase inhibitor, ONO-2235, on the development of diabetic neuropathy in streptozotocin-treated rats.
Hotta N; Kakuta H; Fukasawa H; Kimura M; Koh N; Iida M; Terashima H; Morimura T; Sakamoto N
Diabetologia; 1985 Mar; 28(3):176-80. PubMed ID: 3922829
[TBL] [Abstract][Full Text] [Related]
11. Fidarestat (SNK-860), a potent aldose reductase inhibitor, normalizes the elevated sorbitol accumulation in erythrocytes of diabetic patients.
Asano T; Saito Y; Kawakami M; Yamada N;
J Diabetes Complications; 2002; 16(2):133-8. PubMed ID: 12039395
[TBL] [Abstract][Full Text] [Related]
12. Fructose-3-phosphate production and polyol pathway metabolism in diabetic rat hearts.
Lal S; Randall WC; Taylor AH; Kappler F; Walker M; Brown TR; Szwergold BS
Metabolism; 1997 Nov; 46(11):1333-8. PubMed ID: 9361695
[TBL] [Abstract][Full Text] [Related]
13. Influence of glucose, fructose and aldose reductase inhibition on retinal sorbitol metabolism.
Naeser P; Brolin SE
Acta Ophthalmol (Copenh); 1991 Oct; 69(5):591-5. PubMed ID: 1776411
[TBL] [Abstract][Full Text] [Related]
14. Effect of aldose reductase inhibitor on the inhibition of platelet aggregation induced by diabetic rat plasma.
Takiguchi Y; Wada K; Nakashima M
Eur J Pharmacol; 1992 May; 215(2-3):289-91. PubMed ID: 1396993
[TBL] [Abstract][Full Text] [Related]
15. Polyol pathway in tissues of spontaneously diabetic Chinese hamsters (Cricetulus griseus) and the effect of an aldose reductase inhibitor, ONO-2235.
Sekiguchi M; Watanabe K; Eto M; Iwashima Y; Morikawa A; Takahashi M; Ishii K; Makino I
Comp Biochem Physiol B; 1991; 98(4):637-40. PubMed ID: 1907900
[TBL] [Abstract][Full Text] [Related]
16. Ranirestat has a stronger inhibitory activity on aldose reductase and suppresses inflammatory reactions in high glucose-exposed endothelial cells.
Ishibashi Y; Matsui T; Matsumoto T; Kato H; Yamagishi S
Diab Vasc Dis Res; 2016 Jul; 13(4):312-5. PubMed ID: 27190083
[TBL] [Abstract][Full Text] [Related]
17. Effect of an aldose reductase inhibitor on glomerular basement membrane anionic sites in streptozotocin-induced diabetic rats.
Isogai S; Inokuchi T; Ohe K
Diabetes Res Clin Pract; 1995 Nov; 30(2):111-6. PubMed ID: 8833631
[TBL] [Abstract][Full Text] [Related]
18. Effect of aldose reductase inhibitors on glucose-induced changes in sorbitol and myo-inositol metabolism in human neutrophils.
Suzuki K; Kawamura T; Sakakibara F; Sasaki H; Sano T; Sakamoto N; Hotta N
Diabet Med; 1999 Jan; 16(1):67-73. PubMed ID: 10229296
[TBL] [Abstract][Full Text] [Related]
19. The effects of an aldose reductase inhibitor upon the sorbitol pathway, fructose-1-phosphate and lactate in the retina and nerve of streptozotocin-diabetic rats.
Poulsom R; Mirrlees DJ; Earl DC; Heath H
Exp Eye Res; 1983 May; 36(5):751-60. PubMed ID: 6406254
[TBL] [Abstract][Full Text] [Related]
20. Effect of epalrestat, an aldose reductase inhibitor, on the generation of oxygen-derived free radicals in neutrophils from streptozotocin-induced diabetic rats.
Kashima K; Sato N; Sato K; Shimizu H; Mori M
Endocrinology; 1998 Aug; 139(8):3404-8. PubMed ID: 9681489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
